My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

35.25 +0.52 (+1.50%)

Streaming Delayed Price Updated: 3:06 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

12 Health Care Stocks Moving In Friday's After-Market Session ↗

June 17, 2022

Gainers Travere Therapeutics (NASDAQ:TVTX) stock increased by 16.5% to $28.87 during Friday's after-market session. The market value of their outstanding shares is at $1.8 billion.

Via Benzinga

Analyst Ratings for Travere Therapeutics ↗

May 17, 2022

Within the last quarter, Travere Therapeutics (NASDAQ:TVTX) has observed the following analyst ratings:

Via Benzinga

HC Wainwright & Co. Maintains Buy Rating for Travere Therapeutics: Here's What You Need To Know ↗

May 17, 2022

HC Wainwright & Co. has decided to maintain its Buy rating of Travere Therapeutics (NASDAQ:TVTX) and raise its price target from $45.00 to $46.00. Shares of Travere Therapeutics are trading up 8.5%...

Via Benzinga

Travere Therapeutics Pops After Snagging Priority Review For A New Kidney Drug ↗

May 16, 2022

The FDA will review Travere's drug by mid-November for a kidney disease.

Via Investor's Business Daily

FDA Accepts Travere Therapeutics' NDA for Sparsentan with Priority Review ↗

May 16, 2022

The U.S. Food and Drug Administration (FDA) has accepted Travere Therapeutics’ (NASDAQ: TVTX) New Drug Application (NDA) under Subpart H and granted Priority Review of sparsentan for the treatment of...

Via Benzinga

Earnings Scheduled For October 28, 2021 ↗

October 28, 2021

Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million. •...

Via Benzinga

Here's Why Travere Therapeutics Shares Are Rising Today ↗

May 16, 2022

Travere Therapeutics Inc (NASDAQ: TVTX) shares are trading higher by 7.66% at $23.88 after the company received a priority review from the FDA for its treatment of IgA Nephropathy...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

May 06, 2022

Gainers Kiromic BioPharma (NASDAQ:KRBP) stock increased by 12.6% to $0.58 during Friday's after-market session. The market value of their outstanding shares is at $8.9 million.

Via Benzinga

Earnings Outlook For Retrophin ↗

May 04, 2022

Retrophin (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Retrophin will...

Via Benzinga

The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗

May 02, 2022

Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...

Via Benzinga

The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data ↗

April 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More ↗

April 10, 2022

Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.

Via Benzinga

The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout ↗

March 08, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022 ↗

March 31, 2022

Upgrades

Via Benzinga

Travere Therapeutics: Q4 Earnings Insights ↗

February 24, 2022

Travere Therapeutics (NASDAQ:TVTX) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:01 PM. Here's what investors need to know about the announcement....

Via Benzinga

The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗

February 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022 ↗

February 28, 2022

Upgrades According to DA Davidson, the prior rating for Envestnet Inc (NYSE:ENV) was changed from Neutral to Buy. In the fourth quarter, Envestnet showed an EPS of $0.50, compared...

Via Benzinga

Travere Therapeutics's Earnings: A Preview ↗

February 23, 2022

Travere Therapeutics (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement....

Via Benzinga

Biotech Travere Therapeutics Stock Earns Relative Strength Rating Upgrade ↗

February 14, 2022

Travere shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

Travere Posts Topline Data For Pegtibatinase In patients With Rare Metabolic Disorder ↗

December 15, 2021

Travere Therapeutics Inc (NASDAQ: TVTX) reported topline results from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase for classical homocystinuria (HCU)....

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 28, 2021

Gainers Bellerophon Therapeutics (NASDAQ:

Via Benzinga

The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug ↗

October 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In...

Via Benzinga

PleasrDAO Aint Nothing To F*** With: Wu Tang Clan Album Once Owned By Shkreli Has Been Purchased ↗

October 22, 2021

From the slums of Shaolin, Wu-Tang Clan strikes again. An exclusive album made by the legendary hip-hop group is back in the news ...

Via Benzinga

The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More ↗

October 24, 2021

Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...

Via Benzinga

8 Health Care Stocks With Unusual Options Alerts In Today's Session ↗

September 16, 2021

This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away...

Via Benzinga

The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study ↗

September 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)...

Via Benzinga

Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand

September 16, 2021

From Vifor Pharma Group

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

September 15, 2021

Gainers Larimar Therapeutics (NASDAQ:

Via Benzinga

See Why Travere Therapeutics Stock Moving Higher On Tuesday ↗

September 07, 2021

Travere Therapeutics Inc (NASDAQ: TVTX) has concluded a Type A meeting with the FDA related to sparsentan in focal segmental glomerulosclerosis (FSGS). See:...

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.